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Policy and Ne w
Cris is Standards of Care (CSC) provide a framework for the fair allocation of scarce resources during
emergenc ies, however, there is wide variability in the existence and specificity of CSC across the US
and the authors conclude, "CSC may disproportionately impact disadvantaged populations due to
inequities in comorbid condition prevalence, expected lifespan, and other effects of systemic racism."
Epidemiology
In this large cohort of children (from our own Children's National Hospital) tested for SARS-CoV-2
through a community-based testing site, racial/ethnic minorities and socioeconomically
disadvantaged children carry the highest burden of infection.
A prospective, observational cohort study of the general community (over 2 million individuals in the
UK and US), inc luding nearly 100,000 front-line health-care workers, using self-reported data,
showed risk was increased among front-line health-care workers.
A study of an outbreak of SARS-CoV-2 on a fishing vessel showed that presence of neutralizing
antibodies from prior infection was significantly associated with protection against re-infection.
Disease Presentation, Course, and Complications
Pediatrics
The common clinical pediatric COVID-19 presentations and diagnostic testing are reviewed
inc luding laboratory and radiological features and described treatment and complications. Fever,
cough and lymphopenia, which are common in adult presentation, are not consistently so in pediatric
disease.
CDC has updated their Advisory on multisystem inflammatory syndrome in children (MIS-C) which
is a rare but severe condition that has been reported approximately 2–4 weeks after the onset of
COVID-19 in children and adolescents and advises that clinicians must readily distinguish this from
other severe inflammatory conditions in children.
Analys is of pediatric COVID-19 hospitalization data from 14 states found one in three hospitalized
children was admitted to an intens ive care unit. Children are at risk for severe COVID-19.
Internal Medicine
In a cohort study of patients who had recently recovered from COVID-19, cardiac magnetic
resonance imaging revealed cardiac involvement in 78 patients (78%) and ongoing myocardial
inflammation in 60 patients (60%) highlighting the potential for long-term cardiac consequences of
COVID-19 infection.
Preliminary evidence from a systematic review and meta analysis of 11 cohort students including
nearly 2,000 patients indicates that prophylactic-dose thromboprophylaxis may be inadequate to
control the increased risk of venous thromboembolism (VTE) in patients hospitalized for coronavirus
disease 2019 (COVID-19) infection.
Systematic review of 41 studies and over 5,000 patients provides clinical and radiologic guidance for
early identification of severe COVID-19 patients in order to identify those to transport to specialised
centres and initiation of appropriate treatment.
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A systematic review (62 studies and over 8,000 patients) and meta analysis (26 studies and 4700
patients) show that GI and hepatic involvement should be investigated in patients with COVID-19
since it portends a severe clinical course.
Geriatrics
Four cases of elderly patients developed altered mental status as their primary COVID-19 presenting
symptom without associated fever or respiratory symptoms.
Dermatology
Dermatological les ions are frequent in patients with SARS-CoV-2, especially erythema, urticaria,
and varicella-like rash. The rash is not correlated to the severity of SARS-CoV-2 infection.
Neurology
Cons idering neurological involvement in patients with SARS-CoV-2 infection can result in earlier
diagnos is and treatment. Particularly, young adults with unexplained and unexpected stroke as well
as patients with newly diagnosed Guillain–Barré syndrome should be tested for SARS-CoV-2
infection.
Patients with COVID-19 presenting with acute neurologic symptoms warrant a lower threshold for
suspicion of large vessel stroke, and prompt workup for large vessel stroke is recommended.
Transmission:
Study of the Diamond Princess Cruise Ship shows close-range and long-range transmission likely
contributed s imilarly to disease progression aboard the ship, with fomite transmission playing a
smaller role.
This quality improvement study of samples from an ophthalmology examination room showed viral
material was found on room surfaces, however, the infectivity of the virus samples was unknown.
Viral load was similar between asymptomatic and symptomatic patients; therefore, isolation of
infected persons should be performed regardless of symptoms.
Patients with respiratory manifestations of COVID-19 produce aerosols that contain viable SARSCoV-2 in the absence of aerosol-generating procedures, and these aerosols may serve as a source of
transmission of the virus.
Vertical transmission of SARS-CoV-2 is possible and appears to occur in a minority of cases of
maternal COVID-19 infection in the third trimester.
Assessment of SARS-CoV-2 on an international flight does not rule out the possibility of airborne
transmission in an airplane cabin.
Risk Factors
A prospective population-based cohort study shows that existing use of ACE inhibitors and ARBs
are associated with reduced risks of COVID-19 disease after adjusting for a wide range of variables.
And another large single center retrospective analys is observed a protective effect of prehospitalization use of RAS inhibitors on mortality in hypertens ive COVID-19 patients.
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The Veterans Health Administration analysed EHR of nearly 7,000 Veterans diagnosed with SARS
CoV-2 infection and developed a COVID-19 Care Assessment Need (CAN) score, which is an
efficient way to utilize existing EHR data to predict the clinical course.
A retrospective study identified seven eas ily available prognostic factors and proposed a simple
nomogram for early detection of patients at risk of disease aggravation, in order to optimize clinical
care and initiate specific therapies. Those factors are age, respiratory rate, overweight, temperature,
C-reactive protein, troponin and lymphocyte counts were risk factors of an unfavorable outcome in
hospitalized adult patients.
The BMI plays a significant role in COVID-19 infection and severity at all ages, especially in the
elderly population.
A retrospective observational study found that history of macular degeneration (a proxy for
complement-activation disorders) and history of coagulation disorders (thrombocytopenia,
thrombosis and hemorrhage) are risk factors for SARS-CoV-2-associated morbidity and mortality.
Treatments & Research
Variegated T cell memory to coronaviruses that cause the common cold may underlie at least some
of the extensive heterogeneity observed in COVID-19 disease.
Rhesus macaque models of SARS-CoV-2 infection found that animals developed immune responses
that protected against a second infection.
In a large cohort of hospitalised patients admitted with COVID-19, bacterial, fungal and viral coinfections and superinfections were low; however, when present, they may cause severe diseases
with worse outcomes.
Based on an analys is of 23 RCTs, glucocorticoids were the only intervention with evidence for a
reduction in death compared with standard care.
A clinical practice guideline recommends remdes ivir for patients with severe covid-19.
Good outcomes for patients with critical COVID-19 can be achieved with early noninvas ive–
invasive sequential ventilation and bundled pharmacotherapy.
A review of seven studies, including two RCTs and five cohort studies, with a total of 5444 patients
concludes that convalescent plasma therapy may be an effective therapeutic option, until the
availability of therapeutic and/or prophylactic agents for COVID-19, with some early, promising
evidence on safety, viral clearance, and reduction in mortality. NOTE: On August 23, the US FDA
granted an Emergency Use Authorization for the use of this therapy.
Many trials of potential therapies for COVID-19 disease are underway. Current evidence does not
support a clear role for any specific pharmacotherapy in COVID-19 yet.
There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients
with COVID-19.
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Novaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients.
Given the potential differences in response to anticoagulant therapy, it remains unclear whether
standard dosing effectively achieves the appropriate level of anticoagulation among hospitalized
COVID-19-positive African Americans.
A study found evidence of an association between receipt of the bradykinin 2 receptor antagonist
icatibant and improved oxygenation.
Use of ACEI/ARB does not worsen the prognosis of COVID-19, and could even be protective in
hypertens ive subjects. RAAS inhibitors should be continued in patients who are at risk for, are being
evaluated for, or have COVID-19.
No significant differences among three regimens of several antiviral regimens in effectiveness in
patients with mild to moderate COVID-19 were found in this study.
Vaccines
The inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated
immunogenicity, but longer-term assessment of safety and efficacy will require phase 3 trials.
Diagnostic Testing
The U.S. Food and Drug Administration authorized the first two COVID-19 serology tests that
provide an estimated quantity of antibodies present in the individual’s blood.
Preliminary findings indicate that trained detection dogs can identify respiratory secretion samples
from hospitalized and clinically diseased SARS-CoV-2 infected individuals.
PPE
Facial masks work to prevent the spread of viral particles from asymptomatic individuals to others
and by reducing the inoculum of virus to which a mask-wearer is exposed which will result in milder
disease.
Mandatory mask-wearing policies reduced face-touching behavior among the general population in
public areas.
Nine minutes of UVC irradiation represents a suitable dis infection method for SARS-CoV-2.
RESOURCES
Comprehens ive COVID Care Resources from the Cleveland Clinic is available in English and
Spanish.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------This report was produced by Nathalie Quion, MD, MPH and Himmelfarb Reference Librarians and the GW Covid-19 Intelligence Unit. If
you have a question that the Intelligence Unit can assist you with, or if you would like to provide suggestions or feedback, please email
Dr. Lawrence Deyton, lead for the Intelligence at LDeyton@gwu.edu.
NOTE: Intelligence Reports will be issued monthly with Special Intelligence Reports issued on topics of immediate interest on an as
needed basis. Interim updates are available –see Dr. Akselrod’s Department of Medicine weekly Infectiou s Disease Update available on
the GW Covid-19 Intelligence Reports webpage at https://guides.himmelfarb.gwu.edu/SituationReport
Searchable GW Covid-19 resources can be found through the following links:
GW Covid-19 Research Guide: https://guides.himmelfarb.gwu.edu/covid-19
GW Covid-19 Intelligence Reports: https://guides.h immelfarb.gwu.edu/SituationReport
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